Edited by Peter Hillerberg1 min readStories are generated from ORTEX data and reviewed by the ORTEX team. How we publish
Options markets are sending mixed signals across the semiconductor space this week. Micron Technology sits at the top of both bullish and bearish bets ranked by size over the past seven days. That two-sided positioning reflects genuine uncertainty ahead of a broadly anticipated memory cycle update.
NVIDIA also appears on both sides of the ledger. Positive bets are running alongside a cluster of negative orders. Its RSI sits near 52, mid-range, giving neither bulls nor bears a clear technical edge right now.
The biggest single catalyst trade of the week was in biotech. Vir Biotechnology announced a deal worth up to $1.875 billion with Gilead Sciences. Gilead pays $65 million cash upfront and buys $25 million of stock at $14.16 per share. Vir carries a short score of 57.8 and a days-to-cover of 5.0. That combination of high short interest and a sudden deal announcement is the kind of setup that compresses options premiums on one side fast.
Tesla reports Q3 results on 21 October. Options interest around the earnings date is building. German car registration data tracked by ORTEX Alt Data is running 269% above the same quarter last year, a dataset measured to lead Tesla revenue by 43 days. That reading does not predict the print, but it is pointing higher for the quarter being reported.
UnitedHealth Group is in focus after Baird cut its price target to $427, maintaining a neutral rating. The stock is down slightly on the week. Its RSI of 47.98 and a Q3 earnings call on the calendar suggest options traders are watching for a directional break.
Across the broad market, hotter-than-expected September inflation data is in focus. Futures have held gains despite the number, suggesting the options market is not yet pricing a policy panic.
ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data and reviewed by the ORTEX team. Content is informational only and does not constitute investment advice.
